Trevi Therapeutics Financials - Benzinga

Trevi Therapeutics Inc

TRVINASDAQ

Trade with Public

Trade with Public

$16.60

-0.19-1.13%

At close: Aug 31, 5:00 PM EST

$16.60

N/A

After Hours: 4:00 PM EST

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Trevi Therapeutics Financials

Trevi Therapeutics (TRVI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Trevi Therapeutics Q2 EPS $(0.11), Inline

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 22.22 percent decrease over losses of $(0.09) per share from the same period last year.

Benzinga Newsdesk

PRO
Trevi Therapeutics Q1 EPS $(0.09) Misses $(0.07) Estimate

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.07) by 28.57 percent. This is unchanged from the same period last year.

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

PRO
Trevi Therapeutics Q4 EPS $(0.06) Beats $(0.10) Estimate

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.10) by 41.18 percent. This is a 45.45 percent increase over losses of $(0.11) per share

Benzinga Newsdesk

Earnings Scheduled For March 17, 2026

Benzinga Insights

PRO
Trevi Therapeutics Q3 EPS $(0.08) Beats $(0.10) Estimate

Trevi Therapeutics (NASDAQ:TRVI) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.10) by 23.08 percent. This is a 38.46 percent increase over losses of $(0.13) per share

Benzinga Newsdesk